Journal of Nuclear Cardiology
SCImago
Q1
WOS
Q2
Impact factor
3
SJR
0.954
CiteScore
5.3
Categories
Cardiology and Cardiovascular Medicine
Radiology, Nuclear Medicine and Imaging
Areas
Medicine
Years of issue
1994-2025
journal names
Journal of Nuclear Cardiology
J NUCL CARDIOL
Top-3 citing journals

Journal of Nuclear Cardiology
(15663 citations)

European Journal of Nuclear Medicine and Molecular Imaging
(2454 citations)

Nuclear Medicine Communications
(1460 citations)
Top-3 organizations

University of Alabama at Birmingham
(380 publications)

Yale University
(224 publications)

Brigham and Women's Hospital
(198 publications)

University of Alabama at Birmingham
(82 publications)

Harvard University
(78 publications)

Brigham and Women's Hospital
(74 publications)
Most cited in 5 years
Found
Publications found: 2252
Q3

Role and Responsibilities of Various Stakeholders in Pharmacovigilance (PV)
Phougat P., Beniwal M., Kapoor G., Aggarwal N., Kumari A., Sharma R., Chopra H., Sharma R., Kamal M.A.
Abstract::
In this review paper, we have analyzed the potential and issues associated with Pharmacovigilance
(PV). The analysis is divided into four sections: background, stakeholders, data sources,
and medicinal chemistry. Each section discusses the current state, the future trends, and the best practices
of Pharmacovigilance (PV). The main purpose, methods, results, and implications of our analysis
are summarized.
Background::
Pharmacovigilance (PV) is the science and practice of monitoring, evaluating, understanding,
and preventing adverse drug reactions. Pharmacovigilance (PV) was established by the World
Health Organization in response to the thalidomide tragedy of 1961. The main purpose of Pharmacovigilance
(PV) is to ensure the safety and efficacy of drugs in clinical practice.
Stakeholders::
Pharmacovigilance (PV) involves various stakeholders, such as patients, pharmacists,
pharmaceutical companies, healthcare professionals, and regulatory authorities. Each stakeholder has
a different role and responsibility in reporting, processing, analyzing, and communicating information
about adverse drug reactions. Patient engagement is a key factor for enhancing Pharmacovigilance
(PV) practices.
Data Sources::
Pharmacovigilance (PV) relies on data from various sources, such as clinical trials,
spontaneous reports, electronic medical records, biomedical literature, and patient-reported data in
online health forums. These data sources can provide valuable insights into the real-world use and
safety of drugs, as well as the preferences and needs of patients. However, these data sources also
pose challenges in terms of quality, validity, reliability, and accessibility.
Medicinal Chemistry::
Medicinal chemistry is the branch of chemistry that deals with the design, synthesis,
and evaluation of new drugs and their biological effects. Medicinal chemistry can enhance Pharmacovigilance
(PV) practices by finding new therapeutic indications for existing drugs or compounds that have already
been tested for safety and efficacy. Medicinal chemistry also requires careful design and evaluation of
covalent inhibitors, bi-substrate inhibitors, stabilizers of protein non-effective conformations, and hydrophobic
pocket modifiers to ensure their safety and efficacy.
Implications::
Pharmacovigilance (PV) is a dynamic and evolving discipline that requires collaboration,
regulation, education, and innovation to improve patient safety and care. This review aims to
provide a comprehensive overview of the potential and issues associated with Pharmacovigilance
(PV) practices.
Q2

A Comprehensive Review on Nanoparticles as Drug Delivery System and Their Role for Management of Hypertension
Prerna, Bhatt D.C., Mir K.B., Kumar V., Rathor S.
<p>The current global epidemic of hypertension is not a disease in and of itself but rather
a significant risk factor for serious cardiovascular conditions such as peripheral artery disease,
heart failure, myocardial infarction, and stroke. Although many medications that work through
various mechanisms of action are available on the market in conventional formulations to treat
hypertension, these medications face significant difficulties with their bioavailability, dosing,
and associated side effects, which significantly reduces the effectiveness of their therapeutic
interventions. Numerous studies have shown that nanocarriers and nanoformulations can minimize
the toxicity associated with high doses of the drug while greatly increasing the drug's bioavailability
and reducing the frequency of dosing.
</p>
<p>
This review sheds light on the difficulties posed by traditional antihypertensive formulations and
highlights the necessity of oral nanoparticulate systems to solve these issues. Because hypertension
has a circadian blood pressure pattern, chronotherapeutics can be very important in treating
the condition. On the other hand, nanoparticulate systems can be very important in managing
hypertension.</p>
Q3

Feasting on the Future: Unveiling Edible Insects as a Sustainable Food with Enriched Health Benefits
Kumar A., Goyal N., Pramanik J., Joia S., Singh S., Prajapati B.G.
Abstract:
Animal- and plant-based foods are considered staple foods worldwide. As the population increases, new alternative foods with higher nutritional value and sustainable nature are needed. Moreover, the current food system drastically impacts the environment and may result in unsustainability. The livestock sector significantly contributes to greenhouse gas emissions and is a
major user of land and water resources. Additionally, excessive animal farming adversely affects
the environment, accelerating climate change. To solve these problems, alternative and eco-friendly food resources that offer proper nutritional and health benefits are needed. Although edible insects have been used through several civilizations, they have emerged as an exciting and promising approach. Edible insects can transform various organic products into high-quality proteins
with essential amino acids, including agricultural and food waste products. Edible insects are nutritionally rich and contain healthy fatty acids such as lauric acid, oleic acid, and omega 3 and 6. In
addition, edible insect production requires much less resources, such as water and land, and emits
significantly less greenhouse gases, thus contributing to sustainable food production. This review
provides a comprehensive understanding of the nutritional profile, sustainability aspects, and
health benefits of edible insects.
Q3

Comparative Evaluation of Cefixime Microspheres Utilizing a Natural Polymer and a Synthetic Polymer
Arora D., Taneja Y., Sharma A., Sharma P., Jatin, Guarve K., Rani N., Verma I.
Background::
Microspheres are naturally biodegradable, free-flowing powders with a particle
size of less than 200 micrometres that are comprised of proteins or synthetic polymers. Using
microspheres is a reliable strategy to ensure that the drug is accurately delivered to the target area and
that the right concentration is kept there without having any unfavourable side effects.
Objective::
The objective of the present study was to create a sustained-release cefixime trihydrate
microsphere delivery system employing natural and synthetic polymers as a carrier and increase therapeutic
effectiveness.
Methods::
Due to the simplicity of processing, the solvent injection method was used to create microspheres.
Microspheres were created with this technology using the sustained-release polymer, sodium
alginate, and active material (drug). The compatibility of components with the drug was evaluated
using XRD and FT-IR. In an in-vitro release research, the dissolving medium was phosphate buffer
at pH 6.8. For the kinetic analysis of the drug release mechanism, graphs for zero-order, first-order,
Higuchi's, Korsmeyer-Peppas, and Hixson-Crowell models were also created.
Results::
The best formulation was chosen from the batches, and in-vitro cefixime trihydrate release
studies for various microspheres containing cefixime trihydrate in phosphate buffer (pH 7.4) for 8
hours were performed. The dissolution profiles of formulations F4 and F8 showed that the formulation,
including xanthan gum, F8, released 55.01% more medication in 8 hours than the formulation
using HPMC, F4. X-ray diffraction, swelling index of drug-laden microspheres, and Scanning Electron
Microscopy were used to evaluate formulation F8. The graphs for zero-order, first-order, Higuchi's,
Korsmeyer-Peppas, and Hixson- Crowell models were plotted, and the optimised batch was
discovered to match Higuchi's drug release kinetics with an R2 value of 0.990.
Conclusion::
Cefixime trihydrate microspheres can be utilized as a new drug delivery technology to
minimize dose frequency and, as a result, to promote patient compliance.
Q2

Anticancer Potential of Pineapple and its Bioactive Compound Bromelain
Kumar D., Suchitra, Mundlia J., Yadav S.K., Yadav D., Aggarwal N., Chopra H., Kumar V., Kamal M.A.
Abstract:
Various ailments have been treated with pineapple [Ananas comosus (L.) Merr.] throughout medicinal
history. Pineapple and its bioactive compound bromelain possess health-promoting benefits. Detailed information
on the chemotherapeutic activities of pineapple and its bioactive compound bromelain is provided
in this review, which analyses the current literature regarding their therapeutic potential in cancer. Research
on disease models in cell cultures is the focus of much of the existing research. Several studies have demonstrated
the benefits of pineapple extract and bromelain for in vitro and in vivo cancer models. Preliminary animal
model results show promise, but they must be translated into the clinical setting. Research on these compounds
represents a promising future direction and may be well-tolerated.
Q3

Anti-inflammatory and Anti-arthritic Properties of Mucuna gigantea Plant Extracts: Establishing by Molecular Docking Study
kumar S., Srivastava P., Mujwar S., Gauttam V., Gupta S.
Background:
Mucuna giganteais a traditional plant reported in the management of nervous disorders, male infertility, etc., and also exhibits aphrodisiac, anti-oxidant, and anti-diabetic properties. Very few studies are conducted on Mucuna gigantea. It has not been pharmacologically evaluated for rheumatoid arthritis (RA). In RA, the body's natural defence mechanism gets confused and begins to target the healthy tissues in the body, which leads to joint pain, swelling, bone erosion, and joint stiffness. It is a condition that is classified as an auto-immune disorder.
Methods:
In-silico docking depicted that beta-sitosterol is present in Mucuna gigantea out of ligand library prepared based on a literature survey using computational analysis. Inflammation was induced by carrageen and chronic inflammation was induced by Freund’s complete adjuvant in the plantar surface of the rats. The petroleum ether, ethanolic and aqueous extracts in three divided doses (75, 150, and 300 mg/kg) were administered orally. Diclofenac sodium (10 mg/kg), prednisolone (5 mg/kg), and methotrexate (0.5 mg/kg) were used as standard. The statistical significance between means was analyzed using one-way ANOVA, followed by Dunnett’s multiple range test. The values are expressed as mean ± SD for each group
(n=6), and aP<0.0001, bP<0.001, and cP<0.05 were compared with a negative control group.
Results:
Ethanolic and petroleum ether extracts showed a statistically significant aP<0.0001 effect at 3hr with 300mg/kg effect in
analgesic activity, whereas aqueous extracts showed statistically significant aP<0.0001 effect at 1.5hr with 150 and 300mg/kg. In the
carrageen-induced model, all three extracts at 300 mg/kg showed a statistically significant aP<0.0001 effect from 2- 4hr. In Freund’s
adjuvant model, all three extracts at all doses showed a statistically significant aP<0.0001 effect. Also, Mucuna gigantea remarkably
ameliorated altered WBCs, rheumatoid factor, and positively modified radiographic and histopathological changes.
Conclusion:
Taken together, these results support the traditional use of Mucuna gigantea as a potent anti-inflammatory and anti-arthritic
agent that may be proposed for rheumatoid arthritis treatment.
Q3

A Concise Review on Magnetic Nanoparticles: Their Properties, Types, Synthetic Methods, and Current Trending Applications
M. M., R. B., Kumar S.K., R. S.K.
Abstract:
In recent years, there has been significant research on developing magnetic nanoparticles (MNPs) with multifunctional characteristics. This review focuses on the properties and various types of MNPs, methods of their synthesis, and biomedical, clinical, and other applications.
These syntheses of MNPs were achieved by various methods, like precipitation, thermal, pyrolysis, vapor deposition, and sonochemical. MNPs are nano-sized materials with diameters ranging
from 1 to 100 nm. The MNPs have been used for various applications in biomedical, cancer
theranostic, imaging, drug delivery, biosensing, environment, and agriculture. MNPs have been
extensively researched for molecular diagnosis, treatment, and therapeutic outcome monitoring
in a range of illnesses. They are perfect for biological applications, including cancer therapy,
thrombolysis, and molecular imaging, because of their nanoscale size, surface area, and absence
of side effects. In particular, MNPs can be used to conjugate chemotherapeutic medicines (or)
target ligands/proteins, making them beneficial for drug delivery. However, up until that time,
some ongoing issues and developments in MNPs include toxicity and biocompatibility, targeting
accuracy, regulation and safety, clinical translation, hyperthermia therapy, immunomodulatory
effects, multifunctionality, and nanoparticle aggregation.
Q2

Serum Gamma Glutamyl Transferase: Understanding its Contribution as a Potential Predictor of the Occurrence of Type 2 Diabetes
Anupam S., Goel S., Bhatti K., Mehta D.K., Das R.
Introduction:
The liver and kidneys are the primary locations of the glutathione metabolism enzyme gamma-glutamyl transferase (GGT). The two main factors contributing to an
increase are hepatic illnesses and excessive alcohol use. This study set out to test a theory on the
predictive importance of the association between GGT and Type 2 diabetes mellitus. (T2DM).
Methods:
In order to do this, we combed through PubMed, Google Scholar, Medline, and Science Direct for a wide range of information from previous studies. Attributes were established at
the outset and compared to GGT concentration.
Result:
GGT, present in most cells, absorbs glutathione for intracellular antioxidant defences.
This study links GGT to hepatic enzymes including HDL, LDL, and triglyceride. LDL, triglycerides, AST, and ALT increased with GGT concentration, but LDL decreased. Because of obesity,
GGT production rises with BMI. We found that greater GGT levels were associated with more
T2DM after analysing data from multiple sources.
Conclusion:
This literature review concludes that GGT is related to other factors such as BMI,
HDL, AST, and triglycerides in the development of diabetes mellitus. Serum GGT was found to
be a potential predictor of metabolic syndrome and T2DM
Q2

Evaluation of Moringa Oleifera Leaf Extract for its In vitro Antibacterial Properties, Mechanism of Action, and In vivo Corneal Ulcer Healing Effects in Rabbits’ Eyes
Bibi A., dhanawat M., Aman S., Chauhan S., Chalotra R., Mujwar S., Kaur N., Maivagna C., Gupta S.
Background:
M. oleifera is the most adapted tree species in different medicinal eco-systems
and has resilience against climate changes. This multiple-use tree provides healthy foods,
snacks, honey, and fuel. Besides this, it has immense promising applications by offering antimicrobial
and antibacterial activities for targeted uses. This validates the court of Hippocrates that let
food be the medicine and medicine be the food for which moringa qualifies.
Objective:
The objective of this study is to assess the antioxidant properties of M. oleifera, in
vitro antibacterial activity of hydro-ethanolic extract, and further investigate in vivo healing potential
of M. oleifera for corneal ulcers and in silico analysis.
Methods:
To evaluate the antioxidant and in vitro antibacterial potency of the hydro-ethanolic extract
of M. oleifera on clinically isolated multidrug-resistant strains of Staphylococcus aureus using
agar well diffusion assay. Furthermore, in vivo, healing response of M. oleifera extract was
analysed on corneal ulcers induced in rabbit eyes infected with methicillin-resistant Staphylococcus
aureus.
Results:
The M. oleifera extract exhibited exponential antioxidant activity. In-vitro antibacterial
activity was evaluated by agar well diffusion assay showing zone of inhibition ranging from 11.05
± 0.36 to 20 ± 0.40 mm at concentrations of 20, 40, 80, and 160 mg/ml, whereas, in our finding,
no zone of inhibition was observed below 20 mg/ml concentration, which indicated that there is
threshold limit below which the antibacterial activity of M. oleifera extract is not observed. Furthermore,
continuous application of 3% and 5% M. oleifera extract (eye drop) four times a day for
14 consecutive days showed a significant healing response of the eyes of rabbits with corneal ulcers.
Conclusion:
These results suggest that M. oleifera extract could be a viable alternative or in combination
could be used in existing antibacterial therapies for corneal ulcers. Additionally, there is a
possibility of commercial formulation of M. oleifera extract in the form of deliverable pharmaceutical
products; therefore, it should be explored further.
Q2

The Gut Microbiota-Brain Axis: A New Frontier in Alzheimer's Disease Pathology
dhanawat M., Malik G., Wilson K., Gupta S., Gupta N., Sardana S.
Abstract:
Dr. Aloysius Alzheimer, a German neuropathologist and psychiatrist, recognized the
primary instance of Alzheimer's disease (AD) for a millennium, and this ailment, along with its related
dementias, remains a severe overall community issue related to health. Nearly fifty million individuals
worldwide suffer from dementia, with Alzheimer's illness contributing to between 60 and
70% of the instances, estimated through the World Health Organization. In addition, 82 million individuals
are anticipated to be affected by the global dementia epidemic by 2030 and 152 million by
2050. Furthermore, age, environmental circumstances, and inherited variables all increase the likelihood
of acquiring neurodegenerative illnesses. Most recent pharmacological treatments are found in
original hypotheses of disease, which include cholinergic (drugs that show affective cholinergic system
availability) as well as amyloid-accumulation (a single drug is an antagonist receptor of Nmethyl
D-aspartate). In 2020, the FDA provided approval on anti-amyloid drugs. According to
mounting scientific data, this gut microbiota affects healthy physiological homeostasis and has a
role in the etiology of conditions that range between obesity and neurodegenerative disorders like
Alzheimer's. The microbiota-gut-brain axis might facilitate interconnection among gut microbes as
well as the central nervous system (CNS). Interaction among the microbiota-gut system as well as
the brain occurs through the “two-way” microbiota-gut-brain axis. Along this axis, the stomach as
well as the brain develop physiologically and take on their final forms. This contact is constant and
is mediated by numerous microbiota-derived products. The gut microbiota, for instance, can act as
non-genetic markers to set a threshold for maintaining homeostasis or getting ill. The scientific
community has conducted research and found that bowel dysbiosis and gastrointestinal tract dysregulation
frequently occur in Alzheimer's disease (AD) patients. In this review, the effects of the microbiota-
gut-brain axis on AD pathogenesis will be discussed.
Q2

Bioactive Milk Peptides as a Nutraceutical Opportunity and Challenges
Kapoor D.U., Gaur M., Kumar A., Ansari M.N., Prajapati B.
Abstract:
The biotechnology field has witnessed rapid advancements, leading to the development
of numerous proteins and peptides (PPs) for disease management. The production and isolation of
bioactive milk peptides (BAPs) involve enzymatic hydrolysis and fermentation, followed by purification
through various techniques such as ultrafiltration and chromatography. The nutraceutical
potential of bioactive milk peptides has gained significant attention in nutritional research, as these
peptides may regulate blood sugar levels, mitigate oxidative stress, improve cardiovascular
health, gut health, bone health, and immune responses, and exhibit anticancer properties. However,
to enhance BAP bioavailability, the encapsulation method can be used to offer protection
against protease degradation and controlled release. This article provides insights into the composition,
types, production, isolation, bioavailability, and health benefits of BAPs.
Q3

A recent update on Ayurvedic anti-asthmatic formulations: Highlighting the role of major anti-asthmatic plants
Chaudhary J., Bhatia M., Jain A., Sonam, Dhingra A., Chopra B.
Abstract:
Asthma is a chronic heterogeneous airway obstruction disorder defined by a complex cascade of pathophysiological conditions that lead to recurring bronchial hyper-responsiveness and underlying inflammation, lowering the patient’s quality of life. Despite the availability of various synthetic medications for the management of asthma, it has become one of the leading causes of death worldwide. Furthermore, the present allopathic treatment possesses severe long-term negative effects, which make people more attracted to the safer and easily available indigenous traditional and Ayurvedic system of medicine. Ayurveda is regarded as the “Mother of all healing” and “Science of Life,” which treats all the ailments, including asthma, by restoring a balance between three main components of the body- Vata, Pitta, and Dosha. Various clinically effective and less toxic anti-asthmatic Ayurvedic herbal preparations are available for the management of asthma and related complications which act by causing mast cell deactivation, inhibition of Th1, Th2, Th7 response, T-cell suppression, etc., therefore, efforts have been made to compile all the relevant literature related to the ayurvedic anti-asthmatic formulations and scrutinize the efficacy of selected plants present in the majority in those formulations in asthma along with the structure and mode of action of phytoconstituent responsible for designing novel molecules with better efficacy. Research on these selected plants can also have economic significance as various constituents isolated from these plants for their anti-asthmatic effect can further be explored to discover their potential in medicinal, diagnostic and cosmetic field.
Q2

Convection-enhanced Diffusion: A Novel Tactics to Crack the BBB
Dhanawat M., Garima, Wilson K., Gupta S., Chalotra R., Gupta N.
Abstract:
Although the brain is very accessible to nutrition and oxygen, it can be difficult to deliver
medications to malignant brain tumours. To get around some of these issues and enable the use of
therapeutic pharmacological substances that wouldn't typically cross the blood-brain barrier (BBB),
convection-enhanced delivery (CED) has been developed. It is a cutting-edge strategy that gets beyond
the blood-brain barrier and enables targeted drug administration to treat different neurological
conditions such as brain tumours, Parkinson's disease, and epilepsy. Utilizing pressure gradients to
spread the medicine across the target area is the main idea behind this diffusion mechanism. Through
one to several catheters positioned stereotactically directly within the tumour mass, around the tumour,
or in the cavity created by the resection, drugs are given. This method can be used in a variety
of drug classes, including traditional chemotherapeutics and cutting-edge investigational targeted
medications by using positive-pressure techniques. The drug delivery volume must be optimized for
an effective infusion while minimizing backflow, which causes side effects and lowers therapeutic
efficacy. Therefore, this technique provides a promising approach for treating disorders of the central
nervous system (CNS).
Q3

The Fascinating Effects of Flavonoids on Lung Cancer: A Review
Singh D., dhanawat M., Verma I., Gupta S.
Abstract:
Lung cancer has emerged as one of the most often reported illnesses and leading
causes of mortality worldwide. Inefficient, lack of safety, low therapeutic index, unpleasant effects,
and excessive cost have led to a loss of trust in synthetic medications, limiting their use.
Natural compounds have good anticancer potential without unwanted toxic effects. Among
them, flavonoids are the most important compounds. Flavonoids are polyphenolic chemical
compounds abundant in fruits and vegetables and are essential in preventing lung cancer. Their
potent anticancer effects are said to be based on a wide range of biological actions, such as antioxidants,
anti-mutagenesis, anti-inflammation, and differentiation induction, preventing cancer
cell proliferation through regulating signal transduction pathways, triggering cell cycle arrest,
and activating apoptosis or autophagy; anti-invasion; anti-metastasis, altering cancer cell
drug resistance and increasing sensitization to chemotherapy. This review illustrates the most
recent advancements in flavonoids in lung cancer and their associated molecular mechanisms
using information from scientific research studies like in vitro and in vivo clinical trials. It
takes these data into theory and practice.
Q2

An Updated Review on Nanoemulsion: Factory for Food and Drug Delivery
Kumar V., Garg V., Saini N., Aggarwal N., Kumar H., Kumar D., Chopra H., Kamal M.A., Dureja H.
Background:
A nanoemulsion is a colloidal system of small droplets dispersed in
another liquid. It has attracted considerable attention due to its unique properties and various
applications. Throughout this review, we provide an overview of nanoemulsions and how they
can be applied to various applications such as drug delivery, food applications, and pesticide
formulations.
Objective:
This updated review aims to comprehensively overview nanoemulsions and their
applications as a versatile platform for drug delivery, food applications, and pesticide formulations.
Methods:
Research relevant scientific literature across various databases, including PubMed,
Scopus, and Web of Science. Suitable keywords for this purpose include "nanoemulsion," "drug
delivery," and "food applications." Ensure the search criteria include recent publications to ensure
current knowledge is included.
Results:
Several benefits have been demonstrated in the delivery of drugs using nanoemulsions,
including improved solubility, increased bioavailability, and controlled delivery. Nanoemulsions
have improved some bioactive compounds in food applications, including vitamins and antioxidants.
At the same time, pesticide formulations based on nanoemulsions have also improved
solubility, shelf life, and effectiveness.
Conclusion:
The versatility of nanoemulsions makes them ideal for drug delivery, food, and
pesticide formulation applications. These products are highly soluble, bioavailable, and targeted,
providing significant advantages. More research and development are required to implement
nanoemulsion-based products on a commercial scale.
Top-100
Citing journals
2000
4000
6000
8000
10000
12000
14000
16000
|
|
Journal of Nuclear Cardiology
15663 citations, 22.29%
|
|
European Journal of Nuclear Medicine and Molecular Imaging
2454 citations, 3.49%
|
|
Nuclear Medicine Communications
1460 citations, 2.08%
|
|
Journal of Nuclear Medicine
1315 citations, 1.87%
|
|
Journal of the American College of Cardiology
1163 citations, 1.65%
|
|
Current Cardiovascular Imaging Reports
1106 citations, 1.57%
|
|
Annals of Nuclear Medicine
1034 citations, 1.47%
|
|
JACC: Cardiovascular Imaging
1027 citations, 1.46%
|
|
Seminars in Nuclear Medicine
1015 citations, 1.44%
|
|
Current Cardiology Reports
905 citations, 1.29%
|
|
International Journal of Cardiovascular Imaging
876 citations, 1.25%
|
|
Circulation: Cardiovascular Imaging
702 citations, 1%
|
|
European Heart Journal Cardiovascular Imaging
618 citations, 0.88%
|
|
Circulation
589 citations, 0.84%
|
|
American Journal of Cardiology
586 citations, 0.83%
|
|
International Journal of Cardiology
546 citations, 0.78%
|
|
Annals of Nuclear Cardiology
517 citations, 0.74%
|
|
Frontiers in Cardiovascular Medicine
470 citations, 0.67%
|
|
Clinical Nuclear Medicine
462 citations, 0.66%
|
|
Circulation Journal
447 citations, 0.64%
|
|
Medical Physics
378 citations, 0.54%
|
|
Physics in Medicine and Biology
374 citations, 0.53%
|
|
Cardiology Clinics
346 citations, 0.49%
|
|
Diagnostics
340 citations, 0.48%
|
|
Clinical and Translational Imaging
321 citations, 0.46%
|
|
Journal of Clinical Medicine
298 citations, 0.42%
|
|
EJNMMI Research
290 citations, 0.41%
|
|
Medecine Nucleaire
279 citations, 0.4%
|
|
EJNMMI Physics
252 citations, 0.36%
|
|
European Heart Journal
249 citations, 0.35%
|
|
PET Clinics
241 citations, 0.34%
|
|
Scientific Reports
232 citations, 0.33%
|
|
Journal of Cardiovascular Computed Tomography
231 citations, 0.33%
|
|
Journal of Nuclear Medicine Technology
225 citations, 0.32%
|
|
Heart
219 citations, 0.31%
|
|
PLoS ONE
218 citations, 0.31%
|
|
American Heart Journal
215 citations, 0.31%
|
|
Heart Failure Reviews
199 citations, 0.28%
|
|
Revista Espanola de Cardiologia
199 citations, 0.28%
|
|
Revista Espanola de Medicina Nuclear e Imagen Molecular
195 citations, 0.28%
|
|
Revista Española de Medicina Nuclear
187 citations, 0.27%
|
|
Clinical Physiology and Functional Imaging
179 citations, 0.25%
|
|
Current Problems in Cardiology
178 citations, 0.25%
|
|
Current Opinion in Cardiology
163 citations, 0.23%
|
|
European Radiology
152 citations, 0.22%
|
|
Journal of Cardiology
151 citations, 0.21%
|
|
Journal of the American Heart Association
149 citations, 0.21%
|
|
British Journal of Radiology
148 citations, 0.21%
|
|
International Journal of Molecular Sciences
147 citations, 0.21%
|
|
Nuclear Medicine and Biology
145 citations, 0.21%
|
|
Radiology
143 citations, 0.2%
|
|
IEEE Transactions on Nuclear Science
142 citations, 0.2%
|
|
Canadian Journal of Cardiology
142 citations, 0.2%
|
|
The Carnitine System
142 citations, 0.2%
|
|
Progress in Cardiovascular Diseases
141 citations, 0.2%
|
|
Expert Review of Cardiovascular Therapy
140 citations, 0.2%
|
|
Atherosclerosis
139 citations, 0.2%
|
|
Clinical Cardiology
137 citations, 0.19%
|
|
BMC Cardiovascular Disorders
135 citations, 0.19%
|
|
Nuclear Medicine and Molecular Imaging
135 citations, 0.19%
|
|
IEEE Transactions on Medical Imaging
132 citations, 0.19%
|
|
Nuklearmedizin
128 citations, 0.18%
|
|
Revista española de cardiología (English ed.)
125 citations, 0.18%
|
|
Journal of Cardiovascular Magnetic Resonance
124 citations, 0.18%
|
|
Cureus
119 citations, 0.17%
|
|
Journal of the American Society of Echocardiography
118 citations, 0.17%
|
|
Medicine (United States)
117 citations, 0.17%
|
|
Heart Failure Clinics
116 citations, 0.17%
|
|
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
115 citations, 0.16%
|
|
Echocardiography
110 citations, 0.16%
|
|
Molecular Imaging and Biology
110 citations, 0.16%
|
|
Current Treatment Options in Cardiovascular Medicine
106 citations, 0.15%
|
|
Future Cardiology
105 citations, 0.15%
|
|
Der Nuklearmediziner
105 citations, 0.15%
|
|
American Journal of Roentgenology
103 citations, 0.15%
|
|
Journal of Medical Imaging and Radiation Sciences
102 citations, 0.15%
|
|
Heart and Vessels
93 citations, 0.13%
|
|
American Journal of Physiology - Heart and Circulatory Physiology
93 citations, 0.13%
|
|
Journal of Cardiovascular Development and Disease
92 citations, 0.13%
|
|
Circulation Research
90 citations, 0.13%
|
|
Nature Reviews Cardiology
89 citations, 0.13%
|
|
Journal of Cardiac Failure
88 citations, 0.13%
|
|
Cardiology in Review
87 citations, 0.12%
|
|
Netherlands Heart Journal
86 citations, 0.12%
|
|
Frontiers in Medicine
83 citations, 0.12%
|
|
Life
81 citations, 0.12%
|
|
Russian Journal of Cardiology
79 citations, 0.11%
|
|
Japanese Journal of Radiological Technology
79 citations, 0.11%
|
|
Journal of Cardiovascular Medicine
77 citations, 0.11%
|
|
Coronary Artery Disease
77 citations, 0.11%
|
|
Physica Medica
76 citations, 0.11%
|
|
Pharmaceuticals
75 citations, 0.11%
|
|
Herz
74 citations, 0.11%
|
|
Journal of Magnetic Resonance Imaging
72 citations, 0.1%
|
|
International Heart Journal
71 citations, 0.1%
|
|
Radiographics
69 citations, 0.1%
|
|
ESC heart failure
66 citations, 0.09%
|
|
European Journal of Radiology
65 citations, 0.09%
|
|
BioMed Research International
64 citations, 0.09%
|
|
Molecular Imaging
64 citations, 0.09%
|
|
Show all (70 more) | |
2000
4000
6000
8000
10000
12000
14000
16000
|
Citing publishers
5000
10000
15000
20000
25000
30000
|
|
Springer Nature
26789 citations, 38.12%
|
|
Elsevier
13822 citations, 19.67%
|
|
Ovid Technologies (Wolters Kluwer Health)
4671 citations, 6.65%
|
|
Wiley
2663 citations, 3.79%
|
|
MDPI
1750 citations, 2.49%
|
|
Society of Nuclear Medicine
1549 citations, 2.2%
|
|
Oxford University Press
1478 citations, 2.1%
|
|
Frontiers Media S.A.
921 citations, 1.31%
|
|
Institute of Electrical and Electronics Engineers (IEEE)
819 citations, 1.17%
|
|
Taylor & Francis
806 citations, 1.15%
|
|
The Japanese Society of Nuclear Cardiology
550 citations, 0.78%
|
|
IOP Publishing
502 citations, 0.71%
|
|
SAGE
497 citations, 0.71%
|
|
The Japanese Circulation Society
482 citations, 0.69%
|
|
Georg Thieme Verlag KG
462 citations, 0.66%
|
|
BMJ
428 citations, 0.61%
|
|
Hindawi Limited
385 citations, 0.55%
|
|
Radiological Society of North America (RSNA)
288 citations, 0.41%
|
|
Public Library of Science (PLoS)
240 citations, 0.34%
|
|
American Chemical Society (ACS)
228 citations, 0.32%
|
|
Bentham Science Publishers Ltd.
211 citations, 0.3%
|
|
AME Publishing Company
197 citations, 0.28%
|
|
American Physiological Society
183 citations, 0.26%
|
|
Nippon-Shinzobyo-Gakkai/Japanese College of Cardiology
173 citations, 0.25%
|
|
British Institute of Radiology
163 citations, 0.23%
|
|
Cold Spring Harbor Laboratory
148 citations, 0.21%
|
|
S. Karger AG
140 citations, 0.2%
|
|
American Society of Echocardiography
125 citations, 0.18%
|
|
Baishideng Publishing Group
112 citations, 0.16%
|
|
American Roentgen Ray Society
111 citations, 0.16%
|
|
Silicea - Poligraf, LLC
105 citations, 0.15%
|
|
Royal Society of Chemistry (RSC)
101 citations, 0.14%
|
|
Netherlands Society of Cardiology
92 citations, 0.13%
|
|
Mary Ann Liebert
90 citations, 0.13%
|
|
86 citations, 0.12%
|
|
Radcliffe Media Media Ltd
85 citations, 0.12%
|
|
Japanese Society of Radiological Technology
81 citations, 0.12%
|
|
American Diabetes Association
75 citations, 0.11%
|
|
International Heart Journal (Japanese Heart Journal)
70 citations, 0.1%
|
|
Medknow
69 citations, 0.1%
|
|
The Heart Failure Association of the European Society of Cardiology
64 citations, 0.09%
|
|
American Medical Association (AMA)
62 citations, 0.09%
|
|
Cambridge University Press
59 citations, 0.08%
|
|
Walter de Gruyter
57 citations, 0.08%
|
|
Spandidos Publications
53 citations, 0.08%
|
|
SPIE-Intl Soc Optical Eng
53 citations, 0.08%
|
|
Japanese Society of Internal Medicine
53 citations, 0.08%
|
|
Sociedade Portuguesa De Cardiologia
50 citations, 0.07%
|
|
Edizioni Minerva Medica
44 citations, 0.06%
|
|
Research Square Platform LLC
41 citations, 0.06%
|
|
International Research Journals (OMICS)
37 citations, 0.05%
|
|
Europa Ed
34 citations, 0.05%
|
|
Compuscript, Ltd.
33 citations, 0.05%
|
|
APO Society of Specialists in Heart Failure
32 citations, 0.05%
|
|
Korean Society of Echocardiography
30 citations, 0.04%
|
|
IOS Press
29 citations, 0.04%
|
|
Cardiological Society of India
28 citations, 0.04%
|
|
American Society for Pharmacology and Experimental Therapeutics
25 citations, 0.04%
|
|
JMIR Publications
25 citations, 0.04%
|
|
Japan Society of Sarcoidosis and other Granulomatous Disorders
25 citations, 0.04%
|
|
Chonnam National University Medical School
24 citations, 0.03%
|
|
IntechOpen
24 citations, 0.03%
|
|
Cardiology Research Institute
24 citations, 0.03%
|
|
The Korean Society of Radiology
24 citations, 0.03%
|
|
ifmbe proceedings
23 citations, 0.03%
|
|
OAE Publishing Inc.
23 citations, 0.03%
|
|
Media Sphere Publishing House
23 citations, 0.03%
|
|
The Korean Society of Radiology
23 citations, 0.03%
|
|
Korean Society of Circulation
22 citations, 0.03%
|
|
20 citations, 0.03%
|
|
20 citations, 0.03%
|
|
The Japanese Coronary Association
20 citations, 0.03%
|
|
Asian Society of Cardiovascular Imaging
20 citations, 0.03%
|
|
Proceedings of the National Academy of Sciences (PNAS)
19 citations, 0.03%
|
|
The Endocrine Society
19 citations, 0.03%
|
|
Siberian State Medical University
19 citations, 0.03%
|
|
Eco-Vector LLC
18 citations, 0.03%
|
|
Savezno Ministarstvo Odbrane
18 citations, 0.03%
|
|
Mark Allen Group
18 citations, 0.03%
|
|
Massachusetts Medical Society
17 citations, 0.02%
|
|
Hellenic Cardiological Society
17 citations, 0.02%
|
|
FSBEI HE I.P. Pavlov SPbSMU MOH Russia
17 citations, 0.02%
|
|
Pleiades Publishing
16 citations, 0.02%
|
|
King Saud University
16 citations, 0.02%
|
|
16 citations, 0.02%
|
|
Portland Press
16 citations, 0.02%
|
|
IGI Global
15 citations, 0.02%
|
|
King Faisal Specialist Hospital and Research Centre
14 citations, 0.02%
|
|
Sociedad Brasileira De Cardiologia
14 citations, 0.02%
|
|
The Korean Society of Cardiology
14 citations, 0.02%
|
|
AIP Publishing
13 citations, 0.02%
|
|
American Society for Biochemistry and Molecular Biology
13 citations, 0.02%
|
|
Canadian Science Publishing
13 citations, 0.02%
|
|
Arterialnaya Gipertenziya
13 citations, 0.02%
|
|
Intermedservice Ltd
13 citations, 0.02%
|
|
Scientific Research Publishing
13 citations, 0.02%
|
|
Hans Publishers
13 citations, 0.02%
|
|
PeerJ
12 citations, 0.02%
|
|
American College of Physicians
12 citations, 0.02%
|
|
Consilium Medicum
12 citations, 0.02%
|
|
Show all (70 more) | |
5000
10000
15000
20000
25000
30000
|
Publishing organizations
50
100
150
200
250
300
350
400
|
|
University of Alabama at Birmingham
380 publications, 3.9%
|
|
Yale University
224 publications, 2.3%
|
|
Brigham and Women's Hospital
198 publications, 2.03%
|
|
Harvard University
188 publications, 1.93%
|
|
University of Ottawa
184 publications, 1.89%
|
|
Emory University
170 publications, 1.75%
|
|
University of California, Los Angeles
130 publications, 1.33%
|
|
Cleveland Clinic
120 publications, 1.23%
|
|
Mayo Clinic
113 publications, 1.16%
|
|
Columbia University
106 publications, 1.09%
|
|
Massachusetts General Hospital
88 publications, 0.9%
|
|
Leiden University Medical Center
86 publications, 0.88%
|
|
Houston Methodist Hospital
85 publications, 0.87%
|
|
University Hospital of Zürich
78 publications, 0.8%
|
|
University of Michigan
76 publications, 0.78%
|
|
Istituti di Ricovero e Cura a Carattere Scientifico
66 publications, 0.68%
|
|
NewYork-Presbyterian Hospital
66 publications, 0.68%
|
|
Johns Hopkins University
63 publications, 0.65%
|
|
Icahn School of Medicine at Mount Sinai
62 publications, 0.64%
|
|
University of Connecticut
61 publications, 0.63%
|
|
University of Missouri–Kansas City
60 publications, 0.62%
|
|
Rush University Medical Center
60 publications, 0.62%
|
|
University Medical Center Groningen
59 publications, 0.61%
|
|
Turku PET Centre
56 publications, 0.57%
|
|
Hokkaido University
54 publications, 0.55%
|
|
Institute of Biostructure and Bioimaging
52 publications, 0.53%
|
|
Rush University
52 publications, 0.53%
|
|
Turku University Hospital
50 publications, 0.51%
|
|
University at Buffalo, State University of New York
50 publications, 0.51%
|
|
Northwestern University
49 publications, 0.5%
|
|
Brown University
49 publications, 0.5%
|
|
Amsterdam University Medical Center
47 publications, 0.48%
|
|
University of Twente
44 publications, 0.45%
|
|
Cornell University
44 publications, 0.45%
|
|
Albert Einstein College of Medicine
44 publications, 0.45%
|
|
Drexel University
40 publications, 0.41%
|
|
University of California, Irvine
39 publications, 0.4%
|
|
National Autonomous University of Mexico
36 publications, 0.37%
|
|
Washington University in St. Louis
35 publications, 0.36%
|
|
University of Amsterdam
35 publications, 0.36%
|
|
Chinese Academy of Medical Sciences & Peking Union Medical College
34 publications, 0.35%
|
|
Clinical Physiology Institute
34 publications, 0.35%
|
|
Stanford University
34 publications, 0.35%
|
|
Duke University Hospital
34 publications, 0.35%
|
|
University of California, San Francisco
34 publications, 0.35%
|
|
Montreal Heart Institute
33 publications, 0.34%
|
|
University of Maryland, Baltimore
32 publications, 0.33%
|
|
University of Calgary
32 publications, 0.33%
|
|
Autonomous University of Barcelona
31 publications, 0.32%
|
|
Post graduate Institute of Medical Education and Research
30 publications, 0.31%
|
|
Medical University of Vienna
30 publications, 0.31%
|
|
Imperial College London
30 publications, 0.31%
|
|
University of Cincinnati
29 publications, 0.3%
|
|
Capital Medical University
28 publications, 0.29%
|
|
American University of Beirut Medical Center
28 publications, 0.29%
|
|
University of Copenhagen
28 publications, 0.29%
|
|
Kanazawa University
28 publications, 0.29%
|
|
Hospital of the University of Pennsylvania
28 publications, 0.29%
|
|
Columbia University Irving Medical Center
27 publications, 0.28%
|
|
Ludwig Maximilian University of Munich
27 publications, 0.28%
|
|
Isala hospital
27 publications, 0.28%
|
|
University of Rochester Medical Center
27 publications, 0.28%
|
|
Technical University of Munich
26 publications, 0.27%
|
|
Nanjing Medical University
26 publications, 0.27%
|
|
University of Turku
26 publications, 0.27%
|
|
University of Edinburgh
26 publications, 0.27%
|
|
University of Queensland
26 publications, 0.27%
|
|
Royal Melbourne Hospital
26 publications, 0.27%
|
|
Paris Cité University
26 publications, 0.27%
|
|
All India Institute of Medical Sciences, Delhi
25 publications, 0.26%
|
|
International Atomic Energy Agency
25 publications, 0.26%
|
|
Kanazawa University Hospital
25 publications, 0.26%
|
|
University of Florence
25 publications, 0.26%
|
|
Baylor College of Medicine
25 publications, 0.26%
|
|
Kurume University
25 publications, 0.26%
|
|
Aarhus University Hospital
24 publications, 0.25%
|
|
University of Chicago
24 publications, 0.25%
|
|
Manchester University NHS Foundation Trust
23 publications, 0.24%
|
|
Hannover Medical School
23 publications, 0.24%
|
|
Rechts der Isar Hospital
23 publications, 0.24%
|
|
Kagawa University
23 publications, 0.24%
|
|
New York Medical College
23 publications, 0.24%
|
|
National Yang Ming Chiao Tung University
22 publications, 0.23%
|
|
New York University Langone Health
22 publications, 0.23%
|
|
Vrije Universiteit Medical Center
22 publications, 0.23%
|
|
University of Florida
22 publications, 0.23%
|
|
University of Naples Federico II
21 publications, 0.22%
|
|
Boston University
21 publications, 0.22%
|
|
University of Lorraine
20 publications, 0.21%
|
|
Assuta Medical Center
20 publications, 0.21%
|
|
Sapienza University of Rome
20 publications, 0.21%
|
|
Copenhagen University Hospital
20 publications, 0.21%
|
|
University of Pisa
20 publications, 0.21%
|
|
Rhode Island Hospital
20 publications, 0.21%
|
|
Westchester Medical Center
20 publications, 0.21%
|
|
Shahid Beheshti University of Medical Sciences and Health Services
19 publications, 0.2%
|
|
Uppsala University
19 publications, 0.2%
|
|
Skåne University Hospital
19 publications, 0.2%
|
|
University of Brescia
19 publications, 0.2%
|
|
Spedali Civili di Brescia
19 publications, 0.2%
|
|
Show all (70 more) | |
50
100
150
200
250
300
350
400
|
Publishing organizations in 5 years
10
20
30
40
50
60
70
80
90
|
|
University of Alabama at Birmingham
82 publications, 4.94%
|
|
Harvard University
78 publications, 4.7%
|
|
Brigham and Women's Hospital
74 publications, 4.46%
|
|
University of Ottawa
66 publications, 3.97%
|
|
Yale University
56 publications, 3.37%
|
|
Houston Methodist Hospital
43 publications, 2.59%
|
|
Rush University
39 publications, 2.35%
|
|
Massachusetts General Hospital
32 publications, 1.93%
|
|
University of Calgary
31 publications, 1.87%
|
|
Cleveland Clinic
28 publications, 1.69%
|
|
University Hospital of Zürich
24 publications, 1.44%
|
|
Icahn School of Medicine at Mount Sinai
24 publications, 1.44%
|
|
Istituti di Ricovero e Cura a Carattere Scientifico
23 publications, 1.38%
|
|
University of Missouri–Kansas City
22 publications, 1.32%
|
|
Mayo Clinic
22 publications, 1.32%
|
|
Capital Medical University
21 publications, 1.26%
|
|
NewYork-Presbyterian Hospital
21 publications, 1.26%
|
|
Turku University Hospital
20 publications, 1.2%
|
|
University Medical Center Groningen
20 publications, 1.2%
|
|
Emory University
20 publications, 1.2%
|
|
Institute of Biostructure and Bioimaging
19 publications, 1.14%
|
|
Columbia University Irving Medical Center
19 publications, 1.14%
|
|
Rush University Medical Center
19 publications, 1.14%
|
|
University of Michigan
18 publications, 1.08%
|
|
Turku PET Centre
17 publications, 1.02%
|
|
Medical University of Vienna
17 publications, 1.02%
|
|
Kagawa University
17 publications, 1.02%
|
|
Montreal Heart Institute
17 publications, 1.02%
|
|
Northwestern University
16 publications, 0.96%
|
|
Leiden University Medical Center
16 publications, 0.96%
|
|
University of Queensland
15 publications, 0.9%
|
|
University of Twente
14 publications, 0.84%
|
|
Nanjing Medical University
13 publications, 0.78%
|
|
University of Edinburgh
13 publications, 0.78%
|
|
Royal Melbourne Hospital
13 publications, 0.78%
|
|
University of California, Los Angeles
13 publications, 0.78%
|
|
Michigan Technological University
13 publications, 0.78%
|
|
Kurume University
13 publications, 0.78%
|
|
Jichi Medical University Saitama Medical Center
13 publications, 0.78%
|
|
Uppsala University
12 publications, 0.72%
|
|
Chinese Academy of Medical Sciences & Peking Union Medical College
12 publications, 0.72%
|
|
Autonomous University of Barcelona
12 publications, 0.72%
|
|
University of Pennsylvania
12 publications, 0.72%
|
|
Post graduate Institute of Medical Education and Research
11 publications, 0.66%
|
|
University of Copenhagen
11 publications, 0.66%
|
|
University of Brescia
11 publications, 0.66%
|
|
Spedali Civili di Brescia
11 publications, 0.66%
|
|
Prince Charles Hospital
11 publications, 0.66%
|
|
Soochow University (Suzhou)
10 publications, 0.6%
|
|
Copenhagen University Hospital
10 publications, 0.6%
|
|
Kanazawa University
10 publications, 0.6%
|
|
Cornell University
10 publications, 0.6%
|
|
National Autonomous University of Mexico
10 publications, 0.6%
|
|
German Centre for Cardiovascular Research
10 publications, 0.6%
|
|
Amsterdam University Medical Center
10 publications, 0.6%
|
|
University College London
9 publications, 0.54%
|
|
Aarhus University Hospital
9 publications, 0.54%
|
|
Manchester University NHS Foundation Trust
9 publications, 0.54%
|
|
University of Pisa
9 publications, 0.54%
|
|
Albert Einstein College of Medicine
9 publications, 0.54%
|
|
University of Maryland, Baltimore
9 publications, 0.54%
|
|
Hospital of the University of Pennsylvania
9 publications, 0.54%
|
|
University of Rochester Medical Center
9 publications, 0.54%
|
|
University of Texas Health Science Center at Houston
9 publications, 0.54%
|
|
Tomsk National Research Medical Center of the Russian Academy of Sciences
8 publications, 0.48%
|
|
Tsinghua University
8 publications, 0.48%
|
|
Technical University of Munich
8 publications, 0.48%
|
|
University of Lorraine
8 publications, 0.48%
|
|
Uppsala University Hospital
8 publications, 0.48%
|
|
University of Zurich
8 publications, 0.48%
|
|
University of Naples Federico II
8 publications, 0.48%
|
|
University Hospital of Basel
8 publications, 0.48%
|
|
National Yang Ming Chiao Tung University
8 publications, 0.48%
|
|
University of Florence
8 publications, 0.48%
|
|
University of Melbourne
8 publications, 0.48%
|
|
Boston University
8 publications, 0.48%
|
|
Hannover Medical School
8 publications, 0.48%
|
|
Essen University Hospital
8 publications, 0.48%
|
|
Hokkaido University
8 publications, 0.48%
|
|
Brown University
8 publications, 0.48%
|
|
University of Amsterdam
8 publications, 0.48%
|
|
Isala hospital
8 publications, 0.48%
|
|
New York Medical College
8 publications, 0.48%
|
|
Westchester Medical Center
8 publications, 0.48%
|
|
All India Institute of Medical Sciences, Delhi
7 publications, 0.42%
|
|
Iran University of Medical Sciences
7 publications, 0.42%
|
|
University of Turku
7 publications, 0.42%
|
|
International Atomic Energy Agency
7 publications, 0.42%
|
|
University of Southern Denmark
7 publications, 0.42%
|
|
University of Manchester
7 publications, 0.42%
|
|
Fondazione Toscana Gabriele Monasterio
7 publications, 0.42%
|
|
Stanford University
7 publications, 0.42%
|
|
Columbia University
7 publications, 0.42%
|
|
New York University Langone Health
7 publications, 0.42%
|
|
Guangxi Medical University
7 publications, 0.42%
|
|
University Medical Center Utrecht
7 publications, 0.42%
|
|
Kumamoto University
7 publications, 0.42%
|
|
Fudan University
6 publications, 0.36%
|
|
Rambam Health Care Campus
6 publications, 0.36%
|
|
Assuta Medical Center
6 publications, 0.36%
|
|
Show all (70 more) | |
10
20
30
40
50
60
70
80
90
|
Publishing countries
500
1000
1500
2000
2500
3000
3500
|
|
USA
|
USA, 3147, 32.3%
USA
3147 publications, 32.3%
|
Italy
|
Italy, 379, 3.89%
Italy
379 publications, 3.89%
|
Japan
|
Japan, 345, 3.54%
Japan
345 publications, 3.54%
|
Canada
|
Canada, 304, 3.12%
Canada
304 publications, 3.12%
|
Netherlands
|
Netherlands, 298, 3.06%
Netherlands
298 publications, 3.06%
|
United Kingdom
|
United Kingdom, 229, 2.35%
United Kingdom
229 publications, 2.35%
|
China
|
China, 208, 2.14%
China
208 publications, 2.14%
|
France
|
France, 191, 1.96%
France
191 publications, 1.96%
|
Germany
|
Germany, 148, 1.52%
Germany
148 publications, 1.52%
|
Switzerland
|
Switzerland, 137, 1.41%
Switzerland
137 publications, 1.41%
|
Lebanon
|
Lebanon, 97, 1%
Lebanon
97 publications, 1%
|
Australia
|
Australia, 95, 0.98%
Australia
95 publications, 0.98%
|
Denmark
|
Denmark, 86, 0.88%
Denmark
86 publications, 0.88%
|
Spain
|
Spain, 81, 0.83%
Spain
81 publications, 0.83%
|
Israel
|
Israel, 79, 0.81%
Israel
79 publications, 0.81%
|
Brazil
|
Brazil, 77, 0.79%
Brazil
77 publications, 0.79%
|
Finland
|
Finland, 74, 0.76%
Finland
74 publications, 0.76%
|
Austria
|
Austria, 67, 0.69%
Austria
67 publications, 0.69%
|
India
|
India, 65, 0.67%
India
65 publications, 0.67%
|
Mexico
|
Mexico, 57, 0.59%
Mexico
57 publications, 0.59%
|
Republic of Korea
|
Republic of Korea, 54, 0.55%
Republic of Korea
54 publications, 0.55%
|
Sweden
|
Sweden, 51, 0.52%
Sweden
51 publications, 0.52%
|
Belgium
|
Belgium, 40, 0.41%
Belgium
40 publications, 0.41%
|
Greece
|
Greece, 37, 0.38%
Greece
37 publications, 0.38%
|
Iran
|
Iran, 36, 0.37%
Iran
36 publications, 0.37%
|
Singapore
|
Singapore, 25, 0.26%
Singapore
25 publications, 0.26%
|
Cuba
|
Cuba, 24, 0.25%
Cuba
24 publications, 0.25%
|
Argentina
|
Argentina, 23, 0.24%
Argentina
23 publications, 0.24%
|
Poland
|
Poland, 23, 0.24%
Poland
23 publications, 0.24%
|
Saudi Arabia
|
Saudi Arabia, 21, 0.22%
Saudi Arabia
21 publications, 0.22%
|
Turkey
|
Turkey, 15, 0.15%
Turkey
15 publications, 0.15%
|
Chile
|
Chile, 14, 0.14%
Chile
14 publications, 0.14%
|
Russia
|
Russia, 12, 0.12%
Russia
12 publications, 0.12%
|
Portugal
|
Portugal, 12, 0.12%
Portugal
12 publications, 0.12%
|
Egypt
|
Egypt, 11, 0.11%
Egypt
11 publications, 0.11%
|
Pakistan
|
Pakistan, 11, 0.11%
Pakistan
11 publications, 0.11%
|
Colombia
|
Colombia, 9, 0.09%
Colombia
9 publications, 0.09%
|
Thailand
|
Thailand, 7, 0.07%
Thailand
7 publications, 0.07%
|
Uruguay
|
Uruguay, 7, 0.07%
Uruguay
7 publications, 0.07%
|
Ireland
|
Ireland, 6, 0.06%
Ireland
6 publications, 0.06%
|
Norway
|
Norway, 6, 0.06%
Norway
6 publications, 0.06%
|
Slovenia
|
Slovenia, 5, 0.05%
Slovenia
5 publications, 0.05%
|
Czech Republic
|
Czech Republic, 5, 0.05%
Czech Republic
5 publications, 0.05%
|
Cyprus
|
Cyprus, 4, 0.04%
Cyprus
4 publications, 0.04%
|
New Zealand
|
New Zealand, 4, 0.04%
New Zealand
4 publications, 0.04%
|
Serbia
|
Serbia, 4, 0.04%
Serbia
4 publications, 0.04%
|
South Africa
|
South Africa, 4, 0.04%
South Africa
4 publications, 0.04%
|
Hungary
|
Hungary, 3, 0.03%
Hungary
3 publications, 0.03%
|
Jordan
|
Jordan, 3, 0.03%
Jordan
3 publications, 0.03%
|
UAE
|
UAE, 3, 0.03%
UAE
3 publications, 0.03%
|
Venezuela
|
Venezuela, 2, 0.02%
Venezuela
2 publications, 0.02%
|
Vietnam
|
Vietnam, 2, 0.02%
Vietnam
2 publications, 0.02%
|
Lithuania
|
Lithuania, 2, 0.02%
Lithuania
2 publications, 0.02%
|
Nigeria
|
Nigeria, 2, 0.02%
Nigeria
2 publications, 0.02%
|
Jamaica
|
Jamaica, 2, 0.02%
Jamaica
2 publications, 0.02%
|
Algeria
|
Algeria, 1, 0.01%
Algeria
1 publication, 0.01%
|
Qatar
|
Qatar, 1, 0.01%
Qatar
1 publication, 0.01%
|
Costa Rica
|
Costa Rica, 1, 0.01%
Costa Rica
1 publication, 0.01%
|
Malaysia
|
Malaysia, 1, 0.01%
Malaysia
1 publication, 0.01%
|
Peru
|
Peru, 1, 0.01%
Peru
1 publication, 0.01%
|
Philippines
|
Philippines, 1, 0.01%
Philippines
1 publication, 0.01%
|
Show all (31 more) | |
500
1000
1500
2000
2500
3000
3500
|
Publishing countries in 5 years
100
200
300
400
500
600
700
|
|
USA
|
USA, 659, 39.67%
USA
659 publications, 39.67%
|
Canada
|
Canada, 120, 7.22%
Canada
120 publications, 7.22%
|
China
|
China, 114, 6.86%
China
114 publications, 6.86%
|
Italy
|
Italy, 105, 6.32%
Italy
105 publications, 6.32%
|
Japan
|
Japan, 102, 6.14%
Japan
102 publications, 6.14%
|
Netherlands
|
Netherlands, 63, 3.79%
Netherlands
63 publications, 3.79%
|
United Kingdom
|
United Kingdom, 61, 3.67%
United Kingdom
61 publications, 3.67%
|
Switzerland
|
Switzerland, 50, 3.01%
Switzerland
50 publications, 3.01%
|
France
|
France, 45, 2.71%
France
45 publications, 2.71%
|
Australia
|
Australia, 41, 2.47%
Australia
41 publications, 2.47%
|
Germany
|
Germany, 39, 2.35%
Germany
39 publications, 2.35%
|
Denmark
|
Denmark, 32, 1.93%
Denmark
32 publications, 1.93%
|
Austria
|
Austria, 28, 1.69%
Austria
28 publications, 1.69%
|
Finland
|
Finland, 25, 1.51%
Finland
25 publications, 1.51%
|
Sweden
|
Sweden, 25, 1.51%
Sweden
25 publications, 1.51%
|
Brazil
|
Brazil, 24, 1.44%
Brazil
24 publications, 1.44%
|
India
|
India, 24, 1.44%
India
24 publications, 1.44%
|
Spain
|
Spain, 23, 1.38%
Spain
23 publications, 1.38%
|
Israel
|
Israel, 19, 1.14%
Israel
19 publications, 1.14%
|
Mexico
|
Mexico, 17, 1.02%
Mexico
17 publications, 1.02%
|
Iran
|
Iran, 13, 0.78%
Iran
13 publications, 0.78%
|
Poland
|
Poland, 13, 0.78%
Poland
13 publications, 0.78%
|
Lebanon
|
Lebanon, 12, 0.72%
Lebanon
12 publications, 0.72%
|
Russia
|
Russia, 10, 0.6%
Russia
10 publications, 0.6%
|
Greece
|
Greece, 9, 0.54%
Greece
9 publications, 0.54%
|
Singapore
|
Singapore, 9, 0.54%
Singapore
9 publications, 0.54%
|
Argentina
|
Argentina, 8, 0.48%
Argentina
8 publications, 0.48%
|
Cuba
|
Cuba, 8, 0.48%
Cuba
8 publications, 0.48%
|
Saudi Arabia
|
Saudi Arabia, 6, 0.36%
Saudi Arabia
6 publications, 0.36%
|
Portugal
|
Portugal, 5, 0.3%
Portugal
5 publications, 0.3%
|
Belgium
|
Belgium, 5, 0.3%
Belgium
5 publications, 0.3%
|
Republic of Korea
|
Republic of Korea, 5, 0.3%
Republic of Korea
5 publications, 0.3%
|
Thailand
|
Thailand, 5, 0.3%
Thailand
5 publications, 0.3%
|
Pakistan
|
Pakistan, 4, 0.24%
Pakistan
4 publications, 0.24%
|
Egypt
|
Egypt, 3, 0.18%
Egypt
3 publications, 0.18%
|
Colombia
|
Colombia, 3, 0.18%
Colombia
3 publications, 0.18%
|
New Zealand
|
New Zealand, 3, 0.18%
New Zealand
3 publications, 0.18%
|
UAE
|
UAE, 3, 0.18%
UAE
3 publications, 0.18%
|
Turkey
|
Turkey, 3, 0.18%
Turkey
3 publications, 0.18%
|
Uruguay
|
Uruguay, 3, 0.18%
Uruguay
3 publications, 0.18%
|
Chile
|
Chile, 3, 0.18%
Chile
3 publications, 0.18%
|
Jordan
|
Jordan, 2, 0.12%
Jordan
2 publications, 0.12%
|
Czech Republic
|
Czech Republic, 2, 0.12%
Czech Republic
2 publications, 0.12%
|
Ireland
|
Ireland, 1, 0.06%
Ireland
1 publication, 0.06%
|
Norway
|
Norway, 1, 0.06%
Norway
1 publication, 0.06%
|
Serbia
|
Serbia, 1, 0.06%
Serbia
1 publication, 0.06%
|
Show all (16 more) | |
100
200
300
400
500
600
700
|
1 profile journal article
Ku Chih-Hung
24 publications,
300 citations
h-index: 9